Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) ~~Process~~ A process for the preparation of a solid, orally administrable pharmaceutical composition comprising 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) in hydrophilized form, ~~characterized in that~~ comprising the following steps:

   (a) first preparing granules comprising the active compound (I) in hydrophilized form ~~are prepared~~ by moist granulation

   (b) and converting the granules ~~are then converted~~ into the pharmaceutical composition, if appropriate with addition of pharmaceutically suitable additives.

2. (Currently amended) ~~Process~~ The process according to Claim 1, ~~characterized in that~~ wherein the moist granulation method used is fluidized bed granulation.

3. (Currently amended) ~~Process~~ The process according to Claim 1 ~~or 2~~, ~~characterized in that~~ wherein the active compound (I) is employed in crystalline form.

4. (Currently amended) ~~Process~~ The process according to Claim 3, ~~characterized in that~~ wherein the active compound (I) is employed in micronized form.

5. (Currently amended) ~~Process~~ The process according to ~~one of Claims 1 to 4~~ Claim 1, ~~characterized in that~~ wherein the active compound (I) suspended in the granulating liquid is introduced into the moist granulation.

6. (Currently amended) ~~Process~~ The process according to ~~one of Claims 1 to 5~~ Claim 1, wherein the resulting pharmaceutical composition is a tablet rapidly releasing the active compound (I).

7. (Currently amended) ~~Solid~~ A solid, orally administrable pharmaceutical composition prepared by the process according to Claim 1.

8. (Currently amended) ~~Solid~~ A solid, orally administrable pharmaceutical composition, comprising active compound 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene-carboxamide (I) in hydrophilized form.

9. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 8, comprising the active compound (I) in crystalline form.

10. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 9, comprising the active compound (I) in micronized form.

11. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of Claims 7 to 10~~ Claim 7, ~~characterized in that~~ wherein the active compound (I) is present in a concentration of 1 to 60% based on the total mass of the formulation.

12. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of Claims 7 to 11~~ Claim 7, further comprising sodium lauryl sulphate as a wetting agent.

13. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 12, ~~comprising~~ wherein said sodium lauryl sulphate is present in a concentration of 0.1 to 5%, based on the total mass.

14. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of Claims 7 to 13~~ Claim 7, further comprising hydroxypropylmethylcellulose as a hydrophilic binding agent.

15. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 14, ~~comprising~~ wherein said hydroxypropylmethylcellulose in a concentration of 1 to 15%, based on the total mass.

16. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~one of Claims 7 to 15~~ Claim 7 in the form of a tablet.

17. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 16 in the form of a rapid-release tablet.

18. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to Claim 16 ~~or 17~~, characterized in that the tablet is covered with a coating.

19. (Currently amended) ~~Use of the pharmaceutical composition according to one of Claims 7 to 18~~ A method for the prophylaxis and/or treatment of thromboembolic diseases comprising administering an effective amount of the pharmaceutical composition of claim 7.

20. (Currently amended) ~~Use of~~ A method for the prophylaxis and/or treatment of thromboemblic diseases comprising administering an effective amount of 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) in hydrophilized form ~~for preparing a medicament for the prophylaxis and/or treatment of thromboembolic diseases~~.

21. (Cancelled)